Engineered immune cells from cord blood take on stubborn lymphoma

NCT ID NCT06707259

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 33 times

Summary

This early-phase study tests a new treatment made from cord blood cells that are specially trained to find and attack B-cell lymphoma. The therapy, called IL-10/IL-15 CD19-CAR NK, is given to people whose lymphoma has not responded to or has returned after standard treatments. The main goals are to check safety and find the best dose, while also measuring how well it shrinks tumors and how long benefits last.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

the Second Affiliated Hospital, College of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310009, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B-CELL NON HODGKIN LYMPHOMA B-CELL NON HODGKIN LYMPHOMA